Modified DDAH polypeptides and their use to extracorporeally treat a patient's blood to reduce levels of ADMA

Patent metadata

Field	Value
Publication number	US-12227779-B2
Application number	US-202217690657-A
Country	US
Kind code	B2
Filing date	Mar 9, 2022
Priority date	Jul 31, 2017
Publication date	Feb 18, 2025
Grant date	Feb 18, 2025

Abstract

Modified DDAH polypeptides and their uses thereof are provided. Exemplary embodiments provide DDAH polypeptides which include one or more amino acid substitutions, additions, or deletions with natural or non-naturally encoded amino acids, and/or linkage to other biologically active molecules including other DDAH polypeptides, as well as PKEM. Additionally, use of said DDAH polypeptides for treatment of disease, such as heart failure or renal disease, is also provided.

First claim

What is claimed is:

1. A system comprising a DDAH polypeptide for extracorporeally treating a patient's blood and reducing ADMA levels in said blood, said system comprising
a DDAH polypeptide and
a solid support, wherein said DDAH polypeptide is covalently linked to said solid support; and
a device configured to receive a patient's blood and return the blood to the patient's circulation after contact with said solid support, wherein said device comprises said solid support in a configuration that places said solid support in fluid communication with blood that passes through the device, wherein said blood has reduced ADMA levels after contacting the solid support relative to the ADMA levels in the blood prior to contact with the solid support.

2. The system of claim 1 , wherein said device comprises a hemodialysis, ultrafiltration or plasmapheresis system.

3. The system of claim 2 wherein said solid support is configured to be releasably attached to said hemodialysis, plasmapheresis or ultrafiltration system, wherein the attachment of said solid support places the DDAH polypeptide in fluid communication with blood as it flows through the hemodialysis, plasmapheresis or ultrafiltration system.

4. The system of claim 1 wherein the DDAH polypeptide comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; or SEQ ID NO: 14.

5. The system of claim 1 wherein the DDAH polypeptide comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 13.

6. The system of claim 3 wherein the DDAH polypeptide comprises an amino acid sequence having at least 95% sequence identity to a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 13.

7. The system of claim 3 wherein the DDAH polypeptide comprises SEQ ID NO: 13.

8. A system comprising a DDAH polypeptide for extracorporeally treating a patient's blood and reducing ADMA levels in said blood, said system comprising
a solid support;
two or more different DDAH polypeptides covalently linked to said solid support, wherein the two or more different DDAH polypeptides comprise amino acid sequences independently selected from amino acid sequences having at least 95% sequence identity to SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; or SEQ ID NO: 13; and
a device configured to receive a patient's blood and return the blood to the patient's circulation after contact with said solid support, wherein said device comprises said solid support in a configuration that places said solid support in fluid communication with blood that passes through the device, wherein said blood has reduced ADMA levels after contacting the solid support relative to the ADMA levels in the blood prior to contact with the solid support.

9. The system of claim 8 wherein said solid support comprises two or more different DDAH polypeptides covalently linked to said solid support, wherein a first DDAH polypeptide comprises an amino acid sequence of SEQ ID NO: 13, and a second DDAH polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; and SEQ ID NO: 12.

10. A system comprising a DDAH polypeptide for extracorporeally treating a patient's blood, said system comprising
a DDAH polypeptide comprising the amino acid sequence of SEQ ID NO: 17;
a solid support, wherein said DDAH polypeptide is covalently linked to said solid support; and
a device configured to receive a patient's blood and return the treated blood to the patient's circulation, wherein said device comprises said solid support in a configuration that places said solid support in fluid communication with blood that passes through the device.

11. The system of claim 10 wherein said solid support comprises two or more different DDAH polypeptides covalently linked to said solid support, wherein a first DDAH polypeptide comprises the amino acid sequence of SEQ ID NO: 17, and a second DDAH polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, and SEQ ID NO: 23.

12. The system of claim 11 wherein the second DDAH polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, and SEQ ID NO: 23.

13. A method of reducing levels of ADMA in a patient's blood, said method comprising the steps of
removing blood from said patient;
contacting the patient's blood with a DDAH polypeptide; and
returning the blood to the patient's circulation after the blood has been contacted by said DDAH polypeptide, wherein the returned blood has a lower ADMA concentration than the blood originally taken from the patient.

14. The method of claim 13 wherein the step of contacting the patient's blood with the modified DDAH polypeptide comprises
passing the patient's blood through a hemodialysis or plasmapheresis system that comprises said DDAH polypeptide, said DDAH polypeptide comprising
a DDAH amino acid sequence having at least 95% sequence identity to SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 9; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; or SEQ ID NO: 14; and
a solid support, wherein said DDAH polypeptide is covalently linked to said solid support;
said DDAH polypeptide being in fluid communication with the patient's blood passing through said hemodialysis or plasmapheresis system.

Assignees

• Univ Indiana Trustees

Inventors

• Singh Jaipal

Classifications

• C12Y305/03018

  Dimethylargininase (3.5.3.18) · CPC title

• A61K38/50

  acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C12N9/78 Primary

  acting on carbon to nitrogen bonds other than peptide bonds (3.5) · CPC title